[ad_1]
NEW DELHI, Sept. 12 (Xinhua) – An Indian vaccine manufacturer, Bharat Biotech, which is developing the COVID-19 vaccine, namely Covaxin, said the animal trials were successful.
“To summarize, the candidate vaccine was found to elicit strong immune responses. Therefore, it prevents infection and disease in primates after large amounts of exposure to the live SARS-CoV-2 virus,” said the US-based pharmaceutical company. Telangana.
The company took to social media to say that it proudly announces the results of the Covaxin animal study.
“These results demonstrate protective efficacy in a live viral challenge model,” he wrote on Twitter.
According to Bharat Biotech, he had tested his vaccine candidate on four groups of 20 rhesus macaques. Primates were given a “vaccination regimen of two doses of inactivated SARS-CoV-2 vaccine.”
“One group was given placebo, while three groups were immunized with three different candidate vaccines at 0 and 14 days. All macaques were exposed to the viral challenge 14 days after the second dose,” said the manufacturer of the vaccine. “The results showed protective efficacy, increasing SARS-CoV-2-specific IgG and neutralizing antibodies,” the company said, adding that it reduced the replication of the virus in the nasal cavity, throat and lung tissues of monkeys. .
The company further said that no evidence of pneumonia was seen on histopathological examination in the vaccinated groups, unlike the placebo group.
“No adverse events were observed in animals immunized with a two-dose vaccination regimen,” he further said.
Covaxin is among the runners in the race to find a vaccine for COVID-19.
Human trials of Covaxin began in mid-July. In the first week of September, the vaccine maker received clearance from the drug regulator to move Covaxin into the second phase of human testing.
India is the second country most affected by the pandemic in the world.
On Saturday, the number of COVID-19 cases in the country reached 4,659,984, including 77,472 deaths. During the last 24 hours, 97,570 new cases of COVID-19 and 1,201 related deaths were registered in the country. Final product
